Biofrontera (STU:AI10) Dividends Received


STU:AI10 Biofrontera Inc STU:AI10
43 GF Score
Price €8.06
GF Value €3.96
! 7 Warning Signs
View Full Analysis

What is Biofrontera Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:AI10
43GF Score
Biofrontera Inc STU:AI10
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera (STU:AI10) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of €8.06 is trading 103.5% above its estimated GF Value™ of €3.96.

Key valuation signals for STU:AI10:

  • Dividends Received:
  • GF Value™: €3.96 vs. price of €8.06 (103.5% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the STU:AI10 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera Business Description

Other Exchanges BFRI:USA
Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
43GF Score

Get the complete analysis for STU:AI10

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.06
Price
€3.96
GF Value